Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Evaluating In-line Chlorination in Nigeria

14 maggio 2026 aggiornato da: Amy Janel Pickering, University of California, Berkeley

In-line Chlorination for Drinking Water Treatment in Nigeria

This study evaluates the implementation and effectiveness of in-line chlorination (ILC) for improving drinking water quality in rural Nigeria. Unsafe drinking water remains a major contributor to diarrheal disease, particularly among children under five. Inline chlorination is a passive water treatment approach that automatically doses chlorine at community water systems without requiring electricity or daily user action. Two cluster randomized controlled trials will be conducted in Kano State (North-West Nigeria) and Cross River State (South-South Nigeria). Communities will be randomized to either receive in-line chlorination installed at eligible communal water systems or serve as controls with no chlorination. The unit of randomization is a community or a cluster of communities that share water system for drinking water. The primary objective is to estimate the causal impact of in-line chlorination on household drinking water quality. Outcomes include the prevalence of Escherichia coli contamination in tap water and stored household water as well as the presence of free chlorine residual. Secondary objectives assess water source usage and adoption of chlorinated sources, as well as reduction in diarrheal disease. Implementation fidelity and operational performance of chlorination devices will also be monitored.

Panoramica dello studio

Tipo di studio

Interventistico

Iscrizione (Stimato)

2655

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

    • Cross River State
      • Yala, Cross River State, Nigeria
    • Kano State
      • Makuda, Kano State, Nigeria

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Bambino
  • Adulto
  • Adulto più anziano

Accetta volontari sani

Descrizione

Inclusion Criteria:

  • Adult (18+) or emancipated minor (15+) pregnant women and women with children under 5 years old who do not plan to permanently move in the next 12 months.
  • Must be knowledgeable about the household's water collection and management practices

Exclusion Criteria:

  • Non-age-eligible women. Men and non-emancipated minors. Women who do not consent.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Prevenzione
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Arm 1: Inline Chlorination (ILC) with Behavioral Change Communication (BCC)
Communities randomized to this arm will receive inline chlorination installed at eligible communal drinking water systems, such as boreholes or handpumps, and behavioral change communication.
In-line chlorination devices will be installed on all compatible communal water systems within treatment communities. Devices automatically dose chlorine proportional to water flow without requiring electricity or daily user input. Technologies will include TuriTap liquid dosers installed at handpumps and CTI-8 tablet dosers installed at tanks or piped systems. Devices will be calibrated and routinely monitored to maintain chlorine residual within recommended ranges. In addition to device installation, communities will participate in behavior change communication (BCC) activities designed to support understanding and acceptance of chlorinated water. BCC activities will include community sensitization meetings conducted by the implementing partner. Meetings will provide information on the purpose of chlorination through the in-line chlorination devices, expected benefits and limitations, safe water handling practices, and guidance for addressing taste or odor concerns.
Nessun intervento: Arm 2: Control (No Chlorination)
Communities randomized to this arm will not receive inline chlorination during the study period and will continue their usual water collection and treatment practices.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Proportion of water source samples with detectable free chlorine residual.
Lasso di tempo: About 4-, 8-, and 12-month follow ups after device installations
Measured as >0.1 ppm.
About 4-, 8-, and 12-month follow ups after device installations
Proportion of household stored drinking water samples with detectable free chlorine residual.
Lasso di tempo: About 4-, 8-, and 12-month follow ups after device installations
Measured as >0.1 ppm.
About 4-, 8-, and 12-month follow ups after device installations
Proportion of household stored drinking water samples positive for Escherichia coli.
Lasso di tempo: About 4-, 8-, and 12-month follow ups after device installations
Measured as >1 MPN/100 mL of water by culture-based assay
About 4-, 8-, and 12-month follow ups after device installations

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Proportion of water source samples with detectable total chlorine residual.
Lasso di tempo: About 4-, 8-, and 12-month follow ups after device installations
Measured as >0.1 ppm.
About 4-, 8-, and 12-month follow ups after device installations
Concentration of E. coli in water source samples
Lasso di tempo: About 4-, 8-, and 12-month follow ups after device installations
Concentration of E. coli (in log10 MPN/100ml) in water source samples by culture-based assay
About 4-, 8-, and 12-month follow ups after device installations
Concentration of E. coli in household stored water samples
Lasso di tempo: About 4-, 8-, and 12-month follow ups after device installations
Concentration of E. coli (in log10 MPN/100ml) in household stored water samples by culture-based assay
About 4-, 8-, and 12-month follow ups after device installations
Concentration of total coliform bacteria in water source samples
Lasso di tempo: About 4-, 8-, and 12-month follow ups after device installations
Concentration of total coliform bacteria (MPN/100mL) in water source samples
About 4-, 8-, and 12-month follow ups after device installations
Concentration of total coliform bacteria in household stored water samples
Lasso di tempo: About 4-, 8-, and 12-month follow ups after device installations
Concentration of total coliform bacteria (MPN/100mL) in household stored water samples
About 4-, 8-, and 12-month follow ups after device installations
Prevalence of caregiver-reported diarrhea among children under five years of age
Lasso di tempo: About 4-, 8-, and 12-month follow ups after device installations
Measured as the proportion of children under five reported by caregivers to have experienced diarrhea, defined as three or more loose or watery stools within a 24-hour period, during the 7 days preceding the survey.
About 4-, 8-, and 12-month follow ups after device installations
Prevalence of caregiver-reported diarrhea among household members, any age
Lasso di tempo: About 4-, 8-, and 12-month follow ups after device installations
Measured as the proportion of individuals surveyed in the household that have experienced diarrhea, defined as three or more loose or watery stools within a 24-hour period, during the 7 days preceding the survey. Measured for subset of available respondents.
About 4-, 8-, and 12-month follow ups after device installations
Prevalence of diarrhea among female caregivers
Lasso di tempo: Time frame - About 4-, 8-, and 12-month follow ups after device installations
Measured as the proportion of respondents that have experienced diarrhea, defined as three or more loose or watery stools within a 24-hour period, during the 7 days preceding the survey.
Time frame - About 4-, 8-, and 12-month follow ups after device installations

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Proportion of households reporting an ILC-compatible water source as their primary drinking water source
Lasso di tempo: About 4-, 8-, and 12-month follow ups after device installations
Measured as the percentage of surveyed households identifying an ILC-compatible water system as their source of drinking water. ILC-compatible water systems (boreholes, piped systems, or handpumps have chlorinated water in treatment)
About 4-, 8-, and 12-month follow ups after device installations
Proportion of households switching away from ILC-treated water sources
Lasso di tempo: About 4-, 8-, and 12-month follow ups after device installations
Measured as the percentage of households that discontinue use of a chlorinated water system for drinking water compared to baseline.
About 4-, 8-, and 12-month follow ups after device installations
Proportion of households reporting any household-level water treatment
Lasso di tempo: About 4-, 8-, and 12-month follow ups after device installations
Measured as the percentage of households reporting treatment of drinking water prior to consumption (e.g., boiling, filtration, manual chlorination).
About 4-, 8-, and 12-month follow ups after device installations
Time spent on household-level water treatment
Lasso di tempo: About 4-, 8-, and 12-month follow ups after device installations
Time (minutes) reported by households per day on making water safer to drink (gender stratified)
About 4-, 8-, and 12-month follow ups after device installations

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Amy J Pickering, University of California, Berkeley
  • Investigatore principale: Elisa M Maffioli, University of Michigan
  • Investigatore principale: Adamu I Tanko, PhD, Bayero University Kano, Nigeria

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

26 maggio 2026

Completamento primario (Stimato)

31 dicembre 2027

Completamento dello studio (Stimato)

31 dicembre 2027

Date di iscrizione allo studio

Primo inviato

14 maggio 2026

Primo inviato che soddisfa i criteri di controllo qualità

14 maggio 2026

Primo Inserito (Effettivo)

22 maggio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

22 maggio 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

14 maggio 2026

Ultimo verificato

1 maggio 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi